目前探索维迪西妥单抗联合吉西他滨新辅助治疗MIBC的开放、单臂、多中心II期临床研究正在进行中,研究计划入组36例T2-T4aN0M0期膀胱尿路上皮癌患者,患者 HER-2表达 IHC1+及以上且拒绝铂类新辅助化疗或身体状况/肾功能不适合新辅助...
Neoadjuvant treatments for tri- ple-negative breast cancer (TNBC). Ann Oncol 2012;23 Suppl 6: vi35-9.Sousa B, Cardoso F. Neoadjuvant treatment for HER-2 positive and triple-negative breast cancers. Ann Oncol. 2012; 23Suppl 10: x237-42....
已经有人上传了文献,该状态下其他人无法上传,请等待求助人确认该文件是否是他需要的。 如果求助人在 48 小时内还未确认,系统默认应助成功,本求助将自动关闭。 1天前 顾矜 Lv7 上传了文件 待审核 1-s2.0-S0141813024040522-main.pdf (1.89 MB) 回复 1天前 科研通AI2.0 机器人 未找到该文献,机器人...
结合Her-2 CLMB初步分析,Tucatinib联合曲妥珠单抗和卡培他滨是治疗HER2阳性转移性乳 腺癌患者颅内和颅外疾病的有效方案,Tucatinib使颅内进展或死亡的风险下降了68%,使死亡风险下降了42%,Her-2 CLMB是第一个随机试验表明Her-2阳性脑转移乳腺癌患者颅内反应率...
摘要:在所有乳腺癌分子亚型中,人表皮生长因子受体(Her-2)表达阴性的约占85%,数量庞大,由于靶向治疗效果欠佳,因此手术,化疗和放疗成为Her-2阴性乳腺癌重要治疗手段,其中,在手术之前进行新辅助化疗拥有有效地降低临床分期,提高肿瘤切除率,降期保乳保腋窝,提供体内药敏信息等众多优势在Her-2阴性乳腺癌的治疗中发挥着至...
some studies showed that HER-2 was amplified and overexpressed in about 18%～20% of breast cancer patients with HER-2 positive,therefore,the expression level of HER-2 is an independent index for clinical diagnosis and prognosis of breast cancer.Based on this,the purpose of this study is to ...
positiverelatively chemotherapy.Therenothing betweenthe ofHER-2andthe ofNACZThe of expression efficiency expression HER-2doeshasa differenceand determine not significantpre postchemotherapy.To the of ofhormoneand the to expressionreceptors HER-2,canpredictsensitivity NACTof withbreast and todirectthe ...
This researcher decided to pit the oils against each other for treating a form of breast cancer called HER-2. HER-2 is very aggressive. A Potent One-Two Punch Against Breast Cancer For example, some cancer treatments, such as HER-2 targeted therapies, can cause weakening of the heart muscl...
A large body of in vitro and in vivo experimental evidence supports the notion that these cancers are driven by overactive and constitutive HER2 signaling1,2. This understanding has fueled extensive efforts to develop treatments that target the HER2 oncoprotein with several agents already approved ...
(February 24, 2023) – Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one ...